Eurofins stock gains as PDMR share buying and valuation debate draw investor focus

Published on 09/16/2026 at 14:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eurofins stock closed at EUR 73.48 on Euronext Paris on September 15, 2026, up 1.83 percent and near an intrinsic value estimate of EUR 72.53. Director share purchases between September 11 and 15, 2026 underscore confidence as analysts flag a mixed long term track record.

Wissenschaftlerin analysiert Lebensmittelproben mit Pipette im modernen Testlabor — Fotorealistisches Labor mit Pipetten zeigt Eurofins Scientific SE, den Prüfdienstleister mit ISIN FR0014000MR3, bei Probenanalyse, Illustration mit AI erstellt.

Eurofins Scientific SE stock (ISIN FR0014000MR3) ended the September 15, 2026 session on Euronext Paris at EUR 73.48, up 1.83 percent versus the prior close and trading slightly above a fair value estimate of EUR 72.53 that frames the current valuation debate.

PDMR share purchases support Eurofins stock

According to Business Wire on September 16, 2026, Eurofins Scientific SE reported several Director and PDMR share transactions, including an acquisition of 1,000 shares at a price of EUR 71.23 on September 11, 2026 on Euronext Paris (XPAR).

The same disclosure notes further acquisitions of 1,000 Eurofins shares at EUR 72.31 on September 14, 2026 and another 1,000 shares at EUR 72.73 on September 15, 2026, all executed on XPAR and highlighting continued insider buying over three consecutive trading days.Business Wire

Price moves and valuation context

As Investing.com reports, Eurofins Scientific SE shares closed at EUR 73.48 on Euronext Paris on September 15, 2026, gaining 1.83 percent or EUR 1.32 on the day while the CAC 40 index slipped 0.34 percent, meaning the stock outperformed the broader French benchmark by more than 2 percentage points.

In a separate valuation-focused review dated September 16, 2026, Simply Wall St cites a fair value estimate of EUR 72.53 for Eurofins Scientific versus the latest close of EUR 73.48, characterizing the stock as slightly overvalued by around EUR 0.95 per share or roughly 1.3 percent.

The same analysis notes a one day share price return of 1.83 percent, a 90 day share price return of 17.49 percent and a one year total shareholder return of 18.69 percent, contrasted with a five year total shareholder return decline of 37.98 percent that underscores the longer term volatility investors have experienced.Simply Wall St

Accreditation and earnings multiple

According to Simply Wall St, Eurofins Scientific recently secured ISO/IEC 17065 accreditation for its Assurance Product Certification Program, extending third party validation over its activities in dietary supplements and functional foods at a time when the share price has been recovering.

The valuation review points out that Eurofins Scientific currently trades on a price-to-earnings ratio of 27.1 times, which stands below a global life sciences sector average of 36.1 times and only slightly under a fair ratio benchmark of 28.3 times, indicating that while the stock is judged slightly overvalued on a fair value estimate basis, its earnings multiple does not appear extreme relative to peers.Simply Wall St

Stock level and investor takeaway

Per Euronext Paris data as reflected in market overviews, Eurofins Scientific SE shares closed at EUR 73.48 on September 15, 2026, with the ERF ticker on Euronext Paris serving as the primary reference listing for the stock in euros.